NovoCure Ltd Insider Trading for January 2019
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NovoCure Ltd.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in NovoCure Ltd for January 2019.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 28 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 7.15 | 11,874 | 84,899 | 154,673 | |
| Jan 28 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 7.15 | 15,000 | 107,250 | 166,547 | |
| Jan 28 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 50.15 | 11,874 | 595,481 | 21,305 | 33.2 K to 21.3 K (-35.79 %) |
| Jan 28 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 7.15 | 11,874 | 84,899 | 33,179 | 21.3 K to 33.2 K (+55.73 %) |
| Jan 28 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 48.15 | 15,000 | 722,250 | 21,305 | 36.3 K to 21.3 K (-41.32 %) |
| Jan 28 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 7.15 | 15,000 | 107,250 | 36,305 | 21.3 K to 36.3 K (+70.41 %) |
| Jan 28 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Option Exercise | M | 3.44 | 20,000 | 68,800 | 104,743 | |
| Jan 28 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 50.00 | 20,000 | 1,000,000 | 60,000 | 80 K to 60 K (-25.00 %) |
| Jan 28 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Buy | M | 3.44 | 20,000 | 68,800 | 80,000 | 60 K to 80 K (+33.33 %) |
| Jan 28 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 35,000 | 120,400 | 334,663 | |
| Jan 28 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 49.20 | 35,000 | 1,722,000 | 37,149 | 72.1 K to 37.1 K (-48.51 %) |
| Jan 28 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 35,000 | 120,400 | 72,149 | 37.1 K to 72.1 K (+94.22 %) |
| Jan 25 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 35,000 | 120,400 | 369,663 | |
| Jan 25 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 47.35 | 35,000 | 1,657,250 | 37,149 | 72.1 K to 37.1 K (-48.51 %) |
| Jan 25 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 35,000 | 120,400 | 72,149 | 37.1 K to 72.1 K (+94.22 %) |
| Jan 25 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Option Exercise | M | 7.48 | 88,695 | 663,439 | 0 | |
| Jan 25 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 47.48 | 88,695 | 4,211,239 | 171,164 | 259.9 K to 171.2 K (-34.13 %) |
| Jan 25 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Buy | M | 7.48 | 88,695 | 663,439 | 259,859 | 171.2 K to 259.9 K (+51.82 %) |
| Jan 22 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 30,000 | 103,200 | 404,663 | |
| Jan 22 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 45.90 | 30,000 | 1,376,910 | 37,149 | 67.1 K to 37.1 K (-44.68 %) |
| Jan 22 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 30,000 | 103,200 | 67,149 | 37.1 K to 67.1 K (+80.76 %) |
| Jan 22 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Option Exercise | M | 3.44 | 46,863 | 161,209 | 0 | |
| Jan 22 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 46.16 | 13,644 | 629,793 | 171,164 | 184.8 K to 171.2 K (-7.38 %) |
| Jan 22 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 45.80 | 33,219 | 1,521,563 | 184,808 | 218 K to 184.8 K (-15.24 %) |
| Jan 22 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Buy | M | 3.44 | 46,863 | 161,209 | 218,027 | 171.2 K to 218 K (+27.38 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Option Exercise | M | 3.44 | 20,000 | 68,800 | 124,743 | |
| Jan 18 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 45.00 | 20,000 | 900,060 | 60,000 | 80 K to 60 K (-25.00 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Buy | M | 3.44 | 20,000 | 68,800 | 80,000 | 60 K to 80 K (+33.33 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 19.25 | 12,500 | 240,625 | 37,500 | |
| Jan 18 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 11.85 | 12,500 | 148,125 | 37,500 | |
| Jan 18 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 45.00 | 12,500 | 562,538 | 17,087 | 29.6 K to 17.1 K (-42.25 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 19.25 | 12,500 | 240,625 | 29,587 | 17.1 K to 29.6 K (+73.16 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 45.00 | 12,500 | 562,538 | 17,087 | 29.6 K to 17.1 K (-42.25 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 11.85 | 12,500 | 148,125 | 29,587 | 17.1 K to 29.6 K (+73.16 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Option Exercise | M | 3.44 | 100,000 | 344,000 | 46,863 | |
| Jan 18 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Option Exercise | M | 3.44 | 100,000 | 344,000 | 146,863 | |
| Jan 18 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 45.26 | 100,000 | 4,526,400 | 171,164 | 271.2 K to 171.2 K (-36.88 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Buy | M | 3.44 | 100,000 | 344,000 | 271,164 | 171.2 K to 271.2 K (+58.42 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 45.28 | 1,787 | 80,906 | 171,164 | 173 K to 171.2 K (-1.03 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 45.05 | 98,213 | 4,424,397 | 172,951 | 271.2 K to 173 K (-36.22 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Buy | M | 3.44 | 100,000 | 344,000 | 271,164 | 171.2 K to 271.2 K (+58.42 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Kirson Eilon D. | Chief Science Offic ... | Option Exercise | M | 14.37 | 68,813 | 988,843 | 66,522 | |
| Jan 18 2019 | NVCR | NovoCure Ltd | Kirson Eilon D. | Chief Science Offic ... | Option Exercise | M | 14.37 | 100,000 | 1,437,000 | 135,335 | |
| Jan 18 2019 | NVCR | NovoCure Ltd | Kirson Eilon D. | Chief Science Offic ... | Sell | S | 45.25 | 68,813 | 3,113,788 | 109,063 | 177.9 K to 109.1 K (-38.69 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Kirson Eilon D. | Chief Science Offic ... | Buy | M | 14.37 | 68,813 | 988,843 | 177,876 | 109.1 K to 177.9 K (+63.09 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Kirson Eilon D. | Chief Science Offic ... | Sell | S | 45.11 | 100,000 | 4,511,000 | 109,063 | 209.1 K to 109.1 K (-47.83 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Kirson Eilon D. | Chief Science Offic ... | Buy | M | 14.37 | 100,000 | 1,437,000 | 209,063 | 109.1 K to 209.1 K (+91.69 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 7.15 | 15,000 | 107,250 | 181,547 | |
| Jan 18 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 45.15 | 15,000 | 677,250 | 21,305 | 36.3 K to 21.3 K (-41.32 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 7.15 | 15,000 | 107,250 | 36,305 | 21.3 K to 36.3 K (+70.41 %) |
| Jan 16 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 30,000 | 103,200 | 434,663 | |
| Jan 16 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 44.20 | 30,000 | 1,326,000 | 37,149 | 67.1 K to 37.1 K (-44.68 %) |
| Jan 16 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 30,000 | 103,200 | 67,149 | 37.1 K to 67.1 K (+80.76 %) |
| Jan 16 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Option Exercise | M | 3.44 | 100,000 | 344,000 | 246,863 | |
| Jan 16 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Option Exercise | M | 3.44 | 100,000 | 344,000 | 346,863 | |
| Jan 16 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 43.49 | 100,000 | 4,348,800 | 171,164 | 271.2 K to 171.2 K (-36.88 %) |
| Jan 16 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Buy | M | 3.44 | 100,000 | 344,000 | 271,164 | 171.2 K to 271.2 K (+58.42 %) |
| Jan 16 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 43.52 | 100,000 | 4,352,400 | 171,164 | 271.2 K to 171.2 K (-36.88 %) |
| Jan 16 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Buy | M | 3.44 | 100,000 | 344,000 | 271,164 | 171.2 K to 271.2 K (+58.42 %) |
| Jan 14 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 11.46 | 17,500 | 200,550 | 7,463 | |
| Jan 14 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 14.37 | 8,751 | 125,752 | 0 | |
| Jan 14 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 42.00 | 17,500 | 735,070 | 17,087 | 34.6 K to 17.1 K (-50.60 %) |
| Jan 14 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 11.46 | 17,500 | 200,550 | 34,587 | 17.1 K to 34.6 K (+102.42 %) |
| Jan 14 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 42.00 | 8,751 | 367,577 | 17,087 | 25.8 K to 17.1 K (-33.87 %) |
| Jan 14 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 14.37 | 8,751 | 125,752 | 25,838 | 17.1 K to 25.8 K (+51.21 %) |
| Jan 14 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | M | 14.37 | 54,930 | 789,344 | 37,391 | |
| Jan 14 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 41.14 | 34,050 | 1,400,817 | 146,558 | 180.6 K to 146.6 K (-18.85 %) |
| Jan 14 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 40.47 | 20,880 | 844,993 | 180,608 | 201.5 K to 180.6 K (-10.36 %) |
| Jan 14 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Buy | M | 14.37 | 54,930 | 789,344 | 201,488 | 146.6 K to 201.5 K (+37.48 %) |
| Jan 14 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Option Exercise | M | 3.44 | 5,000 | 17,200 | 144,743 | |
| Jan 14 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 39.91 | 5,000 | 199,550 | 60,000 | 65 K to 60 K (-7.69 %) |
| Jan 14 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Buy | M | 3.44 | 5,000 | 17,200 | 65,000 | 60 K to 65 K (+8.33 %) |
| Jan 14 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 30,000 | 103,200 | 464,663 | |
| Jan 14 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 42.35 | 30,000 | 1,270,500 | 37,149 | 67.1 K to 37.1 K (-44.68 %) |
| Jan 14 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 30,000 | 103,200 | 67,149 | 37.1 K to 67.1 K (+80.76 %) |
| Jan 14 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Grant | A | 27.20 | 25 | 680 | 37,149 | 37.1 K to 37.1 K (+0.07 %) |
| Jan 14 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Grant | A | 27.20 | 264 | 7,181 | 171,164 | 170.9 K to 171.2 K (+0.15 %) |
| Jan 11 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Option Exercise | M | 3.44 | 20,000 | 68,800 | 149,743 | |
| Jan 11 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 40.01 | 6,726 | 269,107 | 60,000 | 66.7 K to 60 K (-10.08 %) |
| Jan 11 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 40.00 | 13,274 | 530,960 | 66,726 | 80 K to 66.7 K (-16.59 %) |
| Jan 11 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Buy | M | 3.44 | 20,000 | 68,800 | 80,000 | 60 K to 80 K (+33.33 %) |
| Jan 11 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 7.15 | 15,000 | 107,250 | 196,547 | |
| Jan 11 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 40.15 | 15,000 | 602,250 | 21,305 | 36.3 K to 21.3 K (-41.32 %) |
| Jan 11 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 7.15 | 15,000 | 107,250 | 36,305 | 21.3 K to 36.3 K (+70.41 %) |
| Jan 11 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | M | 11.46 | 25,000 | 286,500 | 16,274 | |
| Jan 11 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | M | 14.37 | 75,000 | 1,077,750 | 92,321 | |
| Jan 11 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 40.00 | 25,000 | 1,000,000 | 146,558 | 171.6 K to 146.6 K (-14.57 %) |
| Jan 11 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Buy | M | 11.46 | 25,000 | 286,500 | 171,558 | 146.6 K to 171.6 K (+17.06 %) |
| Jan 11 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 40.00 | 75,000 | 3,000,000 | 146,558 | 221.6 K to 146.6 K (-33.85 %) |
| Jan 11 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Buy | M | 14.37 | 75,000 | 1,077,750 | 221,558 | 146.6 K to 221.6 K (+51.17 %) |
| Jan 11 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 14.37 | 8,988 | 129,158 | 8,751 | |
| Jan 11 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 40.01 | 3,023 | 120,950 | 17,087 | 20.1 K to 17.1 K (-15.03 %) |
| Jan 11 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 40.00 | 5,965 | 238,600 | 20,110 | 26.1 K to 20.1 K (-22.88 %) |
| Jan 11 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 14.37 | 8,988 | 129,158 | 26,075 | 17.1 K to 26.1 K (+52.60 %) |